Skip to main content
SpringerLink
Log in

Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

In a retrospective study, 43 patients with dysplastic neoplasms of the bone marrow (myelodysplastic syndromes and myelodysplastic/myeloproliferative-overlap neoplasms) associated with marked (grades 2–3) fibrosis were examined. Histopathologic and morphologic findings as well as cytogenetic and molecular results were correlated with clinical endpoints. Multilineage dysplasia (34 of 43 patients, 79 %) and hypercellular bone marrow (64 %) were found in most patients. In ten of 35 patients, poor risk karyotypes according to the International Prognostic Scoring System (IPSS) were recorded. The JAK2 V617F mutation was detected in four of 30 patients (13 %), and the KIT D816V mutation was found in two of 30 patients (6 %). Patients were mainly treated with palliative drugs and best supportive care. After an observation time of 1–41 (median 21) months, ten of 43 patients (23 %) had developed a secondary acute leukemia. The median survival of all 43 patients was 21.4 months (range 1.8–88.2 months). Of all prognostic parameters examined, the blast cell count at diagnosis was found to be a most reliable and most predictive marker concerning survival and leukemia progression. This confirms previous studies in dysplastic bone marrow neoplasms without fibrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

References

  1. Bennett JM, Catovsky D, Daniel MT et al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199

    CAS  PubMed  Google Scholar 

  2. Brunning RD, Bennet JM, Flandrin G et al. (2001) Myelodysplastic syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 61–74

  3. Pagliuca A et al (1989) Myelofibrosis in primary myelodysplastic syndromes: a clinicomorphological study of 10 cases. Br J Haematol 71:499–504

    Article  CAS  PubMed  Google Scholar 

  4. Ohyashiki K, Sasao I, Ohyashiki JH et al (1991) Clinical and cytogenetic characteristics of myelodysplastic syndromes developing myelofibrosis. Cancer 68:178–183

    Article  CAS  PubMed  Google Scholar 

  5. Verhoef GE, De Wolf-Peeters C, Ferrant A et al (1991) Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. Ann Hematol 63:235–241

    Article  CAS  PubMed  Google Scholar 

  6. Maschek H et al (1992) Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol 48:208–214

    Article  CAS  PubMed  Google Scholar 

  7. Lambertenghi-Deliliers G, Annaloro C, Oriani A et al (1993) Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes. Ann Hematol 66:85–91

    Article  CAS  PubMed  Google Scholar 

  8. Marisavljevic D, Rolovic Z, Cemerikic V et al (2004) Myelofibrosis in primary myelodysplastic syndromes. Clin Biol Signif Med Oncol 21(4):325–331

    CAS  Google Scholar 

  9. Buesche G, Teoman H, Wilczak W, Ganser A, Hecker H, Wilkens L, Göhring G, Schlegelberger B, Bock O, Georgi A, Kreipe H (2008) Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 22:313–322

    Article  CAS  PubMed  Google Scholar 

  10. Della Porta MG, Malcovati L, Boveri E et al (2009) Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 27:754–762

    Article  PubMed  Google Scholar 

  11. Santos FPS, Schlette E, Kantarjian H et al. (2009) Myelodysplastic syndrome with fibrosis: experience of a single-institution with 139 patients. Blood 114 (24): Abstract 2775

    Google Scholar 

  12. Horny HP, Sotlar K, Valent P (2007) Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. Leuk Res 31(12):1609–1616

    Article  CAS  PubMed  Google Scholar 

  13. Valent P, Orazi A, Büsche G, Schmitt-Gräff A, George TI, Sotlar K, Streubel B, Beham-Schmid C, Cerny-Reiterer S, Krieger O, Loosdrecht AVD, Kern W, Ogata K, Wimazal F, Csomor J, Varkonyi J, Sperr WR, Werner M, Kreipe H, Horny HP (2010) Standards and impact of hematopathology in myelodysplastic syndromes (MDS). Oncotarget 1:483–496

    PubMed  Google Scholar 

  14. Malcovati L, Germing U, Kuendgen A et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evaluation in myelodysplastic syndromes. J Clin Oncol 25:3503–3510

    Article  PubMed  Google Scholar 

  15. Valent P, Horny HP, Bennet JM, Fonatsch C, Germing U, Greenberg P et al (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from working conference. Leuk Res 31:727–736

    Article  PubMed  Google Scholar 

  16. Thiele J, Kvasnicka HM, Facchetti F et al (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90:1128–1132

    PubMed  Google Scholar 

  17. Brunning R, Orazi A, Germing U et al (2008) Myelodysplastic syndromes, chapter 5. In: Swerdlow S, Campo E, Harris NL et al (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissue, 4th edition. IARC, Lyon, pp 88–103

  18. Greenberg P, Cox C, LeBeau M et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997(89):2079–2088

    Google Scholar 

  19. Malcovati L, Della Porta MG, Strupp C et al (2011) Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 96:1433–1440

    Article  CAS  PubMed  Google Scholar 

  20. Greenberg PL, Tuechler H, Schanz J et al (2012) Revised International Prognostic Scoring System for myelodysplastic syndromes (IPSS-R). Blood 120(12):2454–2465

    Article  CAS  PubMed  Google Scholar 

  21. Cervantes F, Dupriez B, Pereira A et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895–2901

    Article  CAS  PubMed  Google Scholar 

  22. Schanz J, Tüchler H, Sole F et al (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30:820–829

    Article  PubMed  Google Scholar 

  23. Kremer M, Horn T, Dechow T et al (2006) The JAK2 V617F mutation occurs frequently in myelodysplastic / myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis. Leukemia 20:1315–1316

    Article  CAS  PubMed  Google Scholar 

  24. Olsen RJ, Dunphy CH, O’Malley DP et al (2008) The implication of identifying JAK 2 (V617F) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis. J Hematop 1(2):111–117

    Article  PubMed  Google Scholar 

  25. Fritsche-Polanz R, Jordan JH, Feix A et al (2001) Mutation analysis of c-kit in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 113:357–364

    Article  CAS  PubMed  Google Scholar 

  26. Sotlar K, Bache A, Stellmacher F et al (2008) Systemic mastocytosis associated with chronic idiopathic myelofibrosis. J Mol Diagn 10(1):58–66

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. R Development Core Team, R Foundation for Statistical Computing (2009) R: a language and environment for statistical computing [Internet]. Vienna [cited 2009 Apr 17]. Available from: http://www.r-project.org/

  28. Therneau TM, Lumley T (2009) Survival analysis, including penalised likelihood, original report by Thomas Lumley [Internet] [cited 2009 Apr 17]. Available from: http://www.r-project.org/

  29. Steensma DP, Dewald GW, Lasho TL et al (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood 106:1207–1209

    Article  CAS  PubMed  Google Scholar 

  30. Suvajdzic N, Marisavljevic D, Kraguljac N et al (2004) Acute panmyelosis with myelofibrosis: clinical, immunophenotypic and cytogenetic study of twelve cases. Leuk Lymphoma 45:1873–1879

    Article  CAS  PubMed  Google Scholar 

  31. Orazi A (2007) Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic / myeloproliferative diseases. Pathobiology 74(2):97–114

    Article  PubMed  Google Scholar 

  32. Orazi A, Germing U (2008) The myelodysplastic/myeloproliferative diseases with dysplastic features. Leukemia 22:1308–1319

    Article  CAS  PubMed  Google Scholar 

  33. Bacher U, Schnittger S, Kern W, Weiss T, Haferlach T, Haferlach C (2009) Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category. Ann Hematol 88:1207–1213

    Article  PubMed  Google Scholar 

  34. Haase D (2008) Cytogenetic features in myelodysplastic syndromes. Ann Hematol 87:515–526

    Article  PubMed Central  PubMed  Google Scholar 

  35. Haase D, Germing U, Schanz J, Pfeilstöcker M, Noesslinger T, Hildebrandt B, Kuendgen A, Luebbert M, Kunzmann R, Giagounidis AA, Aul C, Truemper L, Krieger O, Stauder R, Mueller TH, Wimazal F, Valent P, Fonatsch C, Steidl C (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110:4385–4395

    Article  CAS  PubMed  Google Scholar 

  36. Yip S-F, So C-C, Chan AY-Y, Liu HS-Y et al (2006) The lack of association between JAK2 V617F mutation and myelodysplastic syndrome with or without myelofibrosis. Leukemia 20:1165

    Article  CAS  PubMed  Google Scholar 

  37. Ohyashiki K, Aota Y, Akahane D et al (2005) The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 19:2359–2360

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Hematology, Stem Cell Transplantation, Haemostaseology and Internal Oncology, KH Elisabethinen, Linz, Austria

    Sigrid Machherndl-Spandl & O. Krieger

  2. Pathologic Department, KH der Barmherzigen Schwestern, Linz, Austria

    W. Sega, H. Bösmüller & Ch. Gruber

  3. Hematologic Department, University of Düsseldorf, Düsseldorf, Germany

    U. Germing & K. Nachtkamp

  4. Institute for Pathology, University of Düsseldorf, Düsseldorf, Germany

    P. Reinecke

  5. Division of Hematology and Hemostaseology, Department of Internal Medicine 1, Medical University of Vienna, Vienna, Austria

    W. R. Sperr, F. Wimazal & P. Valent

  6. Institute of Pathology, Medical University of Vienna, Vienna, Austria

    L. Müllauer

  7. Institute of Pathology, University of Munich, Munich, Germany

    K. Sotlar & H. P. Horny

  8. Ludwig Boltzmann Institute for Leukemia Research and Haematology, Hanusch Hospital, Vienna, Austria

    H. Tüchler

  9. Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria

    P. Valent

  10. Department of Internal Medicine I, KH Elisabethinen, Linz, Austria

    O. Krieger

Authors
  1. Sigrid Machherndl-Spandl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Sega
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Bösmüller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U. Germing
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ch. Gruber
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. Nachtkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Reinecke
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W. R. Sperr
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F. Wimazal
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L. Müllauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. K. Sotlar
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. H. P. Horny
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. H. Tüchler
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. P. Valent
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. O. Krieger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. Krieger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Machherndl-Spandl, S., Sega, W., Bösmüller, H. et al. Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis. Ann Hematol 93, 57–64 (2014). https://doi.org/10.1007/s00277-013-1945-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-1945-4

Keywords

Search

Navigation